Two randomized, double-blind, placebo-controlled, dose-escalation phase 1 studies evaluating BTH1677, a 1, 3–1,6 beta glucan pathogen associated molecular pattern, in healthy volunteer subjects

Background BTH1677 is a beta glucan pathogen associated molecular pattern (PAMP) currently being investigated as a novel cancer therapy. Here, the initial safety and pharmacokinetic (PK) results of BTH1677 in healthy subjects are reported. Subjects and Methods In the Phase 1a single-dosing study, su...

Descripción completa

Detalles Bibliográficos
Autores principales: Halstenson, C. E., Shamp, T., Gargano, M. A., Walsh, R. M., Patchen, M. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4786610/
https://www.ncbi.nlm.nih.gov/pubmed/26865390
http://dx.doi.org/10.1007/s10637-016-0325-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4786610/
https://www.ncbi.nlm.nih.gov/pubmed/26865390
http://dx.doi.org/10.1007/s10637-016-0325-z

Ejemplares similares